Routine Shutdown of Lonza Site Announced
Lonza has announced that its Niacinamide Plant in Nansha, China will be shut down in November and December 2019 for routine maintenance.
Lonza has announced that its Niacinamide Plant in Nansha, China will be shut down in November and December 2019 for routine maintenance. The Nansha site is the production plant for Niacinamide (vitamin B3), a product that is mainly exported to European countries, the Americas, Japan, and Australia, as well as the Chinese market. The routine maintenance and process optimization is expected to take six weeks at the end of the year, the company stated in an Oct. 22, 2019 press release.
In the press release, Lonza confirmed that during the showdown period it will fulfill all orders and contractual obligations.
Source: Lonza
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
